274 results on '"Martin-Castillo, Begoña"'
Search Results
2. Fatty acid synthase (FASN) signalome: A molecular guide for precision oncology.
3. Stratification of cancer and diabetes based on circulating levels of formate and glucose
4. Metformin and breast cancer: an opportunity for pharmacogenetics
5. Metformin and Breast Cancer: Where Are We Now?
6. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions
7. Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin
8. Metformin Is a Pyridoxal-5′-phosphate (PLP)-Competitive Inhibitor of SHMT2
9. Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cells
10. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells
11. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast
12. Metformin: Targeting the Metabolo-Epigenetic Link in Cancer Biology
13. Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity
14. Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo
15. The anti-malarial chloroquine overcomes Primary resistance and restores sensitivity to Trastuzumab in HER2-positive breast cancer
16. Antibody microarray-based technology to rapidly define matrix metalloproteinase (MMP) signatures in patients undergoing resection for primary gastric carcinoma
17. Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
18. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients
19. The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes
20. Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity
21. Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer
22. BRCA1 and acetyl-CoA carboxylase: The metabolic syndrome of breast cancer
23. In silico clinical trials for anti-aging therapies
24. Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy
25. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients
26. The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin
27. An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors
28. Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation
29. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study
30. Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer
31. Metformin directly targets the H3K27me3 demethylase KDM6A/UTX
32. Extra-virgin olive oil contains a metabolo-epigenetic inhibitor of cancer stem cells
33. Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity
34. Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab
35. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells
36. EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells
37. olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors.
38. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells
39. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
40. Metformin and cancer: Quo vadis et cui bono?
41. Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties
42. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas
43. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
44. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant Basal-HER2 subtype of breast cancer
45. An improved axillary staging system using the OSNA assay does not modify the therapeutic management of breast cancer patients
46. Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment
47. Discovery and validation of an INflammatory PROtein-driven GAstric cancer Signature (INPROGAS) using antibody microarray-based oncoproteomics
48. Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile
49. Stem cell-like ALDHbrightcellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin
50. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.